Alzheimer disease: Amyloid-β immunotherapy CAD106 passes first safety test in patients with Alzheimer disease

Nature Reviews Neurology

Volumn 8, Issue 8, 2012, Pages 414-

  Kingwell, Katie ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; CAD 106; IMMUNOGLOBULIN G; IMMUNOMODULATING AGENT; PLACEBO; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; CEREBROSPINAL FLUID; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNOTHERAPY; INJECTION SITE ERYTHEMA; NOTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SWEDEN;

EID: 84865005632     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2012.128     Document Type: Note

References (1)

1. Winblad, B. et al. Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol. 11, 597-604 (2012)